Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (GB:0QZU)
LSE:0QZU
RESEARCH TOOLSreports
Holding GB:0QZU?
Track your performance easily
0QZU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$342.06 - $508.67
Previous Close$483.75
Volume246.00
Average Volume (3M)2.29K
Market Cap
$123.35B
Enterprise Value$118.48B
Total Cash (Recent Filing)$5.80B
Total Debt (Recent Filing)$933.40M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Oct 30, 2024EPS Estimate
$4.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding258,102,203
10 Day Avg. Volume602
30 Day Avg. Volume2,295
Standard Deviation0.07
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)8.35
Price to Sales (P/S)11.84
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.46
Enterprise Value/Gross Profit13.77
Enterprise Value/Ebitda-156.79
Forecast
1Y Price Target
$508.84Price Target Upside5.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Vertex Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Product LaunchVertex launched Casgevy for treating both sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), indicating strong commercial execution.
Regulatory EndorsementVRTX gained regulatory endorsement to expand the Ph1/2 study of stem cell-derived, fully differentiated islet cell therapy VX-880 in Type 1 diabetes, advancing towards pivotal development.
Revenue GuidanceManagement increased 2024 revenue guidance to $10.65B-$10.85B, up 7.9%-9.9% y/y due to 2Q24 performance.
Bears Say
Commercial OpportunityThe commercial opportunity for the pain franchise is expected to be substantially more challenging than is imputed in the valuation.
Financial PerformanceVRTX reported $2.65B (-1% q/q; +6% y/y) in 2Q24 total WW revenue, just below our $2.71B estimate.
ValuationVertex shares currently at a P/E multiple of 27.0x 2025E consensus EPS vs. the mega-cap BioPharma peer average of 13.0x, leading to a Hold rating.
---
0QZU FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest share price was $342.06 and its highest was $508.67 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Currently, no data Available
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Oct 30, 2024 which is in 39 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -$12.83 earnings per share for the quarter, missing the consensus estimate of -$11.626 by -$1.204.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is $4.05.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 258,102,200 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of -$12.83 in its last earnings report, missing expectations of -$11.626. Following the earnings report the stock price went down -2.967%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Antipodes Partners Ltd. It holds Vertex Pharmaceuticals’s shares valued at 60M.
---
Vertex Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$508.84 (5.19% Upside)
$508.84 (5.19% Upside)
Blogger Sentiment
Bullish
GB:0QZU Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.39%
12-Months-Change
Fundamentals
Return on Equity
-3.24%
Trailing 12-Months
Asset Growth
-1.07%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
0QZU Company Deck
---
0QZU Earnings Call
Q2 2024
0:00 / 0:00
---
0QZU Revenue Breakdown
90.63% TRIKAFTA/KAFTRIO
4.82% KALYDECO
3.30% ORKAMBI
1.25% SYMDEKO/SYMKEVI
---
0QZU Stock 12 Month Forecast
Average Price Target
$508.84
▲(5.19% Upside)
Technical Analysis
Best Analysts Covering 0QZU
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+21.09%
reiterated a buy rating 2 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +21.09% per trade.
---